Table 1.

Patients infused with the investigational NK cell-based product

Study subject	Gender	Performance statusa	Stage of diseaseb	Type of M component	Risk group according to FISHc	Bone lesion	BM plasma cells at diagnosis, %
P103	F	1	III/II	IgGκ	SR	Yes	15
P105	F	1	II/II	IgGκ	SR	Yes	60
P106	M	0	II/II	IgGκ	HR	Yes	47
P107	M	1	-d	κe	HR	Yes	39
P110	M	1	II/II	IgAκ	SR	Yes	97
P111	M	1	I/I	IgDκ	SR	Yes	18

^aPerformance status grouped according to Eastern Cooperative Oncology Group (ECOG)²⁶.

^bInternational staging system (ISS)²⁷/revised international staging system (R-ISS)²⁸.

^cSR/HR denoted standard/high risk as classified by the International Myeloma Working Group (IMWG),²⁹ fluorescence in situ hybridization (FISH).

^dStaging not possible due to lack of B₂M analysis at diagnosis.

^eLight-chain kappa.